Cardiology

NCI-CCC Breast Tumor Board Question

Questions discussed in this category

Which regimen would you recommend for a young patient with node-positive, triple-positive breast cancer with significant anthracycline-induced cardiomyopathy?

Question inspired by the case of a young woman with LVEF 20-25%, asymptomatic.

1 Answer available

Papers discussed in this category

N. Engl. J. Med.,

Pembrolizumab for Early Triple-Negative Breast Cancer.

JAMA oncology, 2024 Feb 01

Clinical and Biomarker Findings of Neoadjuvant Pembrolizumab and Carboplatin Plus Docetaxel in Triple-Negative Breast Cancer: NeoPACT Phase 2 Clinical Trial.

Related Topics in Cardiology